Delta Electronics announced on the 18th its plan to acquire up to 177 million shares of ACT Genomics Holdings Company Limited (ACT Genomics) for a maximum of USD 71.78 million (approximately NT$2.146 billion). The deal requires securing over 90% of the company’s shares as a condition for completion. Delta Chairman and CEO Ping Cheng stated that with the aging population and rising incidence of cancer and tumors, medical demand in these areas is expected to grow steadily. Next-generation sequencing (NGS) technology, which can identify multiple disease-related genetic mutations in a single test, offers significant market potential by enabling precision medicine.
Cheng noted that ACT Genomics is a leading cancer diagnostics company in Asia, and its integration into Delta will strengthen the company’s existing capabilities in medical devices and technologies, further enhancing its footprint in the biomedical sector.
He emphasized that ACT Genomics specializes in NGS-based cancer genomic testing, which can be applied across four major stages: early cancer screening, diagnosis, treatment selection, and post-treatment monitoring. This acquisition will deepen Delta’s presence in the rapidly growing precision medicine market.
ACT Genomics CEO Hua-Chien Chen remarked, “Our mission is to make precision medicine more accessible, ensuring every cancer patient can receive the most accurate and effective treatment. Our team integrates oncology, cancer genomics, and bioinformatics to offer comprehensive genetic testing services that support drug selection, disease monitoring, and risk assessment. With Delta’s global reach, we look forward to rapidly expanding into key target markets.”
Founded in 2014, ACT Genomics operates in Taiwan, Singapore, Japan, Thailand, and Hong Kong. It is recognized as a leading cancer genomics company in Asia, equipped with internationally accredited clinical genetic testing laboratories. The company utilizes advanced NGS technology and its proprietary reagents to analyze over 440 tumor-related genes. It is also the first company outside the U.S. to receive an FDA letter of authorization for its comprehensive NGS tumor profiling panel.
Delta highlighted that ACT Genomics supports physicians in tailoring personalized treatment strategies through its robust bioinformatics platform and clinical support team. Its services have been adopted as self-pay medical offerings by over 80 healthcare institutions in Taiwan, with partners including clinical hospitals, global pharmaceutical companies, academic research institutions, and insurance providers.
Delta further explained that the acquisition’s completion is contingent upon meeting certain conditions, primarily the acquisition of over 90% of ACT Genomics’ shares. The per-share purchase price may vary depending on the shareholder’s identity, and the finalization of the transaction is subject to contractual preconditions and approvals from relevant regulatory authorities.
Resource: 台達搶攻生醫、癌症檢測市場 砸21.46億擬收購行動基因股權
